News headlines about Xencor (NASDAQ:XNCR) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xencor earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.7480354551863 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of NASDAQ XNCR opened at $30.10 on Monday. The stock has a market cap of $1,644.82, a PE ratio of -28.67 and a beta of 1.51. Xencor has a 52 week low of $18.55 and a 52 week high of $34.63.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.02. The business had revenue of $10.94 million for the quarter, compared to analyst estimates of $15.65 million. Xencor had a negative return on equity of 16.62% and a negative net margin of 137.35%. analysts expect that Xencor will post -2.09 earnings per share for the current year.
Several brokerages have weighed in on XNCR. BidaskClub raised Xencor from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 9th. Wedbush upped their target price on Xencor from $38.00 to $39.00 and gave the stock an “outperform” rating in a research report on Monday, March 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $37.00 target price on shares of Xencor in a research report on Thursday, March 1st. Leerink Swann reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Xencor in a research report on Wednesday, March 28th. Finally, Nomura dropped their target price on Xencor to $28.00 and set a “neutral” rating on the stock in a research report on Thursday, April 5th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Xencor has an average rating of “Buy” and a consensus price target of $35.17.
In other news, insider Edgardo Baracchini, Jr. sold 40,000 shares of the stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $30.89, for a total transaction of $1,235,600.00. Following the transaction, the insider now owns 40,000 shares of the company’s stock, valued at approximately $1,235,600. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul A. Foster sold 10,000 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $26.03, for a total value of $260,300.00. Following the transaction, the insider now directly owns 12,419 shares in the company, valued at approximately $323,266.57. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,000 shares of company stock worth $3,101,550. 4.03% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/16/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-xencor-xncr-stock-price.html.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.